A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese

Inclusion criteria

• Female at birth.
• Age 18-64 years (both inclusive) at the time of signing the informed consent.
• Body mass index (BMI) between 27.0 kilograms per square meter (kg/m^2) and 39.9 kg/m^2 (both inclusive) at screening.
• Overweight should be due to excess adipose tissue, as judged by the investigator.
• Considered eligible with suitable veins for cannulation or repeated venepuncture, as judged by the investigator.
• No clinically significant findings during medical history, physical examination, vital signs, electrocardiogram or clinical laboratory tests at the screening visit, as assessed by the investigator.

Exclusion criteria

• Known or suspected hypersensitivity to study intervention(s) or related products.
• Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method.
• Current participation (i.e., dosing) in any other interventional clinical study within 90 days before screening.
• Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
• Treatment with any medication prescribed for the indication of obesity or weight management within 90 days before screening, including incretin-based treatment(s).
• Previous or planned (during the study period) obesity treatment with surgery. However, the following are allowed:

• Liposuction and/or abdominoplasty, if performed greater than symbol (>) 1 year before screening.
• Adjustable gastric banding, if the band has been removed > 1 year before screening.
• Intragastric balloon, if the balloon has been removed > 1 year before screening.
• Duodenal-jejunal bypass liner (e.g., Endobarrier), if the sleeve has been removed > 1 year before screening.